Acadia Pharma (ACAD) Reports In-Line Q4 EPS
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $26.40 +0.04%
Revenue Growth %: +19.3%
Financial Fact:
Net loss: -71.61M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Revenue Growth %: +19.3%
Financial Fact:
Net loss: -71.61M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q4 EPS of ($0.65), in-line with the analyst estimate of ($0.65). Revenue for the quarter came in at $11.96 million versus the consensus estimate of $9.05 million.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Deutsche Bank Upgrades Danone SA (BN:FP) (DANOY) to Hold
- William Blair Starts Yesway Inc (YSWY) at Outperform
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
